Malaria parasites in Uganda show mutations linked to drug resistance

Researchers have identified new genetic mutations in malaria parasites that may be reducing the effectiveness of commonly used antimalarial drugs. A study published in Nature Medicine, led by scientists at Brown University, examined the genetic makeup of Plasmodium falciparum—the parasite responsible for the most severe form of human malaria—collected from patients in Uganda.

The study identified a specific genetic combination named the PIN haplotype. This variant was absent in samples from two decades ago but has become widespread, appearing in 84% of sampled parasites in northern Uganda and 55% in eastern Uganda by 2024. Laboratory testing indicates that parasites carrying this variant show reduced susceptibility to several key drugs, including lumefantrine, mefloquine, and dihydroartemisinin.

While the findings do not confirm widespread treatment failure in patients, they indicate that the parasites are evolving under pressure from existing medicines. Scientists are now working to utilize genomic surveillance systems to track these genetic changes and monitor how they impact drug effectiveness over time to protect malaria-control programs.